

Abstract

The present invention relates to a modified adeno-associated virus (AAV) capsid protein and use thereof; said capsid protein comprises substitution of approximately 5 - 14 amino acids with respect to a parent AAV capsid protein; furthermore, the AAV containing the modified capsid protein has increased infectiousness with respect to a target tissue or target cell (e.g. retinal cell) in comparison with an AAV comprising an unmodified parent AAV capsid protein.